Tag Archives: BAL30072

Basilea announced improved operating results in its H1-2013 financials

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data and ceftobiprole regulatory decision in Europe maintained for H2 2013 Significant agreement with BARDA of up to USD 89 million … Read the full press release

Basilea Pharmaceutica Ltd awarded USD 89M contract by U.S. Department of Health and Human Services division BARDA for the development of its novel antibiotic BAL30072

BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA agreement Basel, Switzerland, 26-6-2013 — /europawire.eu/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Biomedical Advanced Research and Development … Read the full press release